Short peptide, application of short peptide as vaccine adjuvant, and vaccine

A vaccine adjuvant and short peptide technology, which is applied to the short peptide, its application as a vaccine adjuvant and the field of vaccines, can solve the problems of high cost, poor safety, difficult synthesis and purification, etc.

Active Publication Date: 2016-10-12
NANKAI UNIV
View PDF4 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these immune adjuvants are either poor in safety, too expensive, not easy to synthesize and purify, or have poor ability to enhance the immune response of antigens, which cannot meet the needs of their clinical use.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Short peptide, application of short peptide as vaccine adjuvant, and vaccine
  • Short peptide, application of short peptide as vaccine adjuvant, and vaccine
  • Short peptide, application of short peptide as vaccine adjuvant, and vaccine

Examples

Experimental program
Comparison scheme
Effect test

preparation Embodiment 1

[0050] Preparation of vaccine vac-1 loaded with OVA protein in short peptide hydrogel at pH 7.0 and room temperature 20°C

[0051] (1) Synthesize the L-configuration short peptide Nap-GFFY by FMOC-solid-phase synthesis method, the structural formula is as follows:

[0052]

[0053] Specific steps are as follows:

[0054] 1) Weigh 0.5mmol 2-cl-Trt resin into a solid-phase synthesizer, add 10mL of anhydrous dichloromethane (hereinafter referred to as DCM), place on a shaker and shake for 5min to fully swell the 2-cl-Trt resin ;

[0055] 2) Remove DCM from the solid-phase synthesizer equipped with 2-cl-Trt resin with ear washing ball;

[0056] 3) Dissolve 0.75 mmol of Fmoc-protected amino acid in 10 mL of anhydrous DCM, add 0.75 mmol of DIEPA, then transfer to the above-mentioned solid-phase synthesizer, add 0.75 mmol of DIEPA, and react at room temperature for 1 h;

[0057] 4) Sealing: Remove the reaction solution in the solid-phase synthesizer with ear wash balls, and the...

preparation Embodiment 2

[0067] Short peptide hydrogel Nap-G at pH 7.0 and room temperature 20°C D f D f D Preparation of vaccine vac-2 loaded with OVA protein

[0068] (1) Synthesis of Nap-G by FMOC-solid phase synthesis method D f D f D Y, the structural formula is as follows:

[0069]

[0070] Specific steps are as follows:

[0071] 1) Weigh 0.5 mmol 2-cl-Trt resin into a solid-phase synthesizer, add 10 mL of DCM, place on a shaker and shake for 5 minutes to fully swell the 2-cl-Trt resin;

[0072] 2) Remove DCM from the solid-phase synthesizer equipped with 2-cl-Trt resin with ear washing ball;

[0073] 3) Dissolve 0.75 mmol of Fmoc-protected amino acid in 10 mL of anhydrous DCM, add 0.75 mmol of DIEPA, then transfer to the above-mentioned solid-phase synthesizer, add 0.75 mmol of DIEPA, and react at room temperature for 1 h;

[0074] 4) Sealing: Remove the reaction solution in the solid-phase synthesizer with ear wash balls, and then wash with anhydrous DCM, each time using 10 mL of DC...

preparation Embodiment 3

[0084] Synthesis of Short Peptide Nap-G by FMOC-Solid Phase Synthesis D f D f D Y D K, the specific steps are as follows:

[0085] 1) Weigh 0.5 mmol 2-cl-Trt resin into a solid-phase synthesizer, add 10 mL of DCM, place on a shaker and shake for 5 minutes to fully swell the 2-cl-Trt resin;

[0086] 2) Remove DCM from the solid-phase synthesizer equipped with 2-cl-Trt resin with ear washing ball;

[0087] 3) Dissolve 0.75 mmol of Fmoc-protected amino acid in 10 mL of anhydrous DCM, add 0.75 mmol of DIEPA, then transfer to the above-mentioned solid-phase synthesizer, add 0.75 mmol of DIEPA, and react at room temperature for 1 h;

[0088]4) Sealing: Remove the reaction solution in the solid-phase synthesizer with the ear washing ball, and then wash with anhydrous DCM, each time the amount of DCM is 10mL, and the washing time is 1min. : 20mL of DIEPA:methanol=17:1:2 solution, reacted at room temperature for 10min;

[0089] 5) Remove the reaction liquid in the solid-phase syn...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a short peptide, application of the short peptide as a vaccine adjuvant, and a vaccine using the short peptide as the vaccine adjuvant. The short peptide is simple to prepare and can improve immune response of antigen after simple physical mixing with the antigen. The sequence of the short peptide is X-GFFYK, wherein X is a terminating group. Preferably, the short peptide is of D configuration. The short peptide can be used as an immunoadjuvant to improve immunogenicity of antigen and allows a main body to undergo intense antigen-specific cellular immune and humoral immune response; the short peptide is applicable to a variety of antigens; and the short peptide is easy to prepare and has a single and controllable component.

Description

technical field [0001] The invention relates to a short peptide, its application as a vaccine adjuvant and a vaccine. Background technique [0002] With the continuous in-depth study of immunology, the increasingly mature genetic engineering technology and the rapid development of synthetic technology, humans have developed a variety of new vaccines such as DNA recombinant vaccines and short peptide vaccines. Although these emerging vaccines have many advantages, such as easy synthesis, purification, and strong antigen specificity, their weak immunogenicity has become their fatal shortcoming, which makes them unable to induce a strong immune response and limits their clinical application. on the use of. In practical application, immune adjuvants are often required to enhance its immunogenicity or enhance the host's specific response to the antigen. So far, aluminum adjuvant is the only adjuvant approved by FDA that can be used in humans. However, it can only stimulate the ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/06C07K5/103A61K39/39
CPCA61K39/39C07K5/1008C07K7/06
Inventor 杨志谋王玲杨成彪王怀民
Owner NANKAI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap